Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria

The Journal of Urology
Howard J HellerC Y Pak

Abstract

We tested whether UroPhos-K, a new slow release neutral form of potassium phosphate (155 mg. phosphate, 8 mEq. potassium per tablet) in a dose of 4 tablets twice daily would produce a sustained hypocalciuric response and maintain bone mass in patients with absorptive hypercalciuria, a major cause of nephrolithiasis characterized by excessive intestinal calcium absorption accompanied in some patients by excessive bone loss. A total of 25 patients with absorptive hypercalciuria were studied in a 4-year, prospective, open trial with UroPhos-K at yearly intervals during a 4-day inpatient physiological study with a constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate daily. Treatment with UroPhos-K caused a sustained, marked reduction in urinary calcium (264 to 181 mg. daily). Fractional 47calcium absorption decreased modestly (74.0 to 64.6%) commensurate with a reduction in serum 1,25-dihydroxyvitamin D (42 to 34 pg./ml.). Intact parathyroid hormone increased within the normal range (30 to 42 pg./ml.). Bone mineral density was stable at the lumbar spine, femoral neck and distal third of the radius. UroPhos-K may provide a long-term alternative for hypercalciuric patients in whom thiazide therapy...Continue Reading

References

Dec 1, 1992·The Journal of Clinical Endocrinology and Metabolism·N A BreslauC Y Pak
Dec 1, 1992·The Journal of Clinical Endocrinology and Metabolism·S A RivkeesJ D Crawford
Dec 1, 1992·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·F PietschmannC Y Pak
Dec 1, 1991·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C Y Pak
May 1, 1991·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·A J YatesG R Mundy
May 1, 1967·Analytical Biochemistry·K I KivirikkoD J Prockop
May 1, 1983·The Journal of Clinical Endocrinology and Metabolism·A E BroadusR Baron
Jan 1, 1982·Calcified Tissue International·A M Yaari, I M Shapiro
Nov 1, 1980·The Journal of Clinical Endocrinology and Metabolism·C J Van Den BergL H Smith
Mar 1, 1995·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·N A BreslauC Y Pak
Mar 1, 1994·Clinica Chimica Acta; International Journal of Clinical Chemistry·Y WatanabeY Seino
Jan 1, 1996·Kidney International·J R WeisingerR Martinis

❮ Previous
Next ❯

Citations

Dec 7, 2011·BJU International·Daniel Spernat, John Kourambas
Dec 12, 2002·Endocrinology and Metabolism Clinics of North America·Loris BorghiAlmerico Novarini
May 23, 2007·Expert Opinion on Pharmacotherapy·Sangtae Park
Oct 27, 2016·Journal of Nephrology·Giovanni GambaroUNKNOWN Consensus Conference Group
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Joaquin EscribanoMarta Roqué I Figuls

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.